Burgdorf – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 548.5 million in the financial year 2023/24 (previous year: CHF 497.5 million). Adjusted for the sale of the diabetes specialist DiaExpert, this corresponds to growth of 24.5 % or CHF 108.0 million. The operating profit (EBIT) amounted to CHF 86.2 million (previous year: CHF 60.6 million). Adjusted for the previous year's contribution from DiaExpert, this results in EBIT growth of CHF 46.8 million or 119 %. On this basis, Ypsomed was able to more than double its EBIT for the second time in a row. Net profit increased by more than half and now amounts to CHF 78.4 million (previous year: CHF 51.3 million). In future, Ypsomed intends to focus on expanding its leading position in Delivery Systems. To this purpose, it is examining strategic options for the Diabetes Care business area.

Read more...

Burgdorf – Ypsomed enters a partnership with ten23 health, a global Swiss contract development and manufacturing organization. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses. ten23’s drug development, filling and device assembly expertise will significantly contribute to the product offering.

Read more...

Burgdorf - Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses. The transfer to MTD will ensure the long-term supply of a unique pen needle offering. With this step, Ypsomed is focusing its diabetes care business even more strongly on the further development and marketing of the innovative mylife Loop insulin pump solution. As part of its growth strategy, Ypsomed will invest over CHF 100 million over the next four years in the expansion of capacities for autoinjectors at the Solothurn site.

Read more...

Ypsomed doubles profits and confirms outlook

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million). 

Read more...

Burgdorf – Pregnant women with type 1 diabetes and their babies benefit from treatment with a hybrid closed loop system based on the CamAPS FX algorithm. This is demonstrated by the AiDAPT clinical study, which clinical outcomes were published in the New England Journal of Medicine and the experience of the pregnant women in Diabetes Technology and Therapeutics, both on 5 October 2023. The algorithm of Ypsomed's mylife Loop, the CamAPS FX app is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes.

Read more...